Q1 2026 Management View “We had a phenomenal start to 2026, delivering $302 million of revenue in Q1, representing 48% year-over-year growth.” (Co-Founder, Co-CEO & Chairman Helmy Eltoukhy) “Our commercial flywheel has achieved a new level of velocity,

Diagnostics company Guardant Health (NASDAQ:GH) reported Q1 CY2026 results , with sales up 48.3% year on year to $301.7 million. The company’s full-year revenue guidance of $1.31 billion at the midpoint came in 3.

Guardant Health (NASDAQ: GH) is on the rise, in more ways than one. Shares of the precision oncology company have skyrocketed over the last six months. Guardant Health has also chalked up several key victories recently, including signing a multi-year ...

On 4 May 2026, Guardant Health announced that the FDA approved its Guardant360 CDx liquid biopsy as a companion diagnostic for VEPPANU, enabling blood-based detection of ESR1 mutations in ER-positive/HER2-negative advanced or metastatic breast cancer after progression on endocrine therapy.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved the Guardant360® CDx liquid biopsy test as a companion diagnostic for VEPPANU (vepdegestrant).

Baron Capital, an investment management company, released its Q1 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here.

The FDA approves blood test to guide breast cancer therapy by detecting ESR1 mutations for targeted treatment selection.

In the last three months, 7 analysts have published ratings on Guardant Health (NASDAQ:GH), offering a diverse range of perspectives from bullish to bearish. The following table provides a quick overview of their recent ratings, highlighting the changing ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced its intention to offer $300.0 million aggregate principal amount of convertible senior notes due 2033 (the ...

A federal court jury has sided with Guardant Health, which had claimed that rival cancer test developer Natera went too far in advertisements for its competing assay to monitor patients for the return of their colorectal tumors. The jury awarded Guardant $ ...

The firm's total revenue increased 48 percent as oncology revenue grew 36 percent and biopharma and data revenue rose 17 percent.